---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087259"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:46:33.556272+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Iovance posts Q2 product revenue $31.1M; guides FY24 $160-165M, FY25 $450-475M

## Summary
- Q2 net loss $97.1M ($0.34/shr) vs. $106.5M ($0.47) a year ago; revenue $31.1M from Amtagvi ($12.8M) and Proleukin ($18.3M).
- FY24 product revenue guidance $160-165M; FY25 $450-475M; Q3 2024 expected $53-55M.
- Over 55 patients infused with Amtagvi since April; >50 ATCs in 29 states; >70 ATCs targeted by year-end.
- Cash $449.6M as of July 24, up from $346.3M at Dec 2023, partly from ~$200M ATM equity raise.
- Lifileucel pipeline: frontline melanoma TILVANCE-301 enrolling globally; NSCLC Phase 2 accelerating; endometrial cancer Phase 2 started.

## SEC filing metadata
- accession: 0001104659-24-087259
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465924087259/0001104659-24-087259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465924087259/tm2421110d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087259
- JSON: https://secwatch.observer/filing/0001104659-24-087259.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087259.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.